CYP2C9*2 Allele Increases Risk for Hypoglycemia in POR*1/*1 Type 2 Diabetic Patients Treated with Sulfonylureas

Abstract It is previously shown that carriers of the defective allele CYP2C9*3 that leads to impaired sulfonylurea metabolism are at increased sulfonylurea-induced hypoglycemia risk due to diminished drug metabolism, whereas no effect of CYP2C9*2 allele was found. Recently, a polymorphism in P450 oxidoreductase (POR) gene, assigned as POR*28 allele, was associated with increased CYP2C9 activity. The aim of this study was to assess i) the effect of POR*28 allele on sulfonylurea-induced hypoglycemia risk and ii) the association of CYP2C9*2 allele with hypoglycemia risk in non-carriers of POR*28 allele. The study group consisted of 176 patients with diagnosed type 2 diabetes mellitus (T2DM) treated with sulfonylureas, of whom 92 patients had experienced at least one drug-associated hypoglycemic event (cases), while 84 had never experienced a hypoglycemic event (controls). POR*28 allele was detected by use of real-time TaqMan PCR. POR*28 allele was not associated with sulfonylurea-induced hypoglycemia. In POR*1/*1 patients, CYP2C9*1/*2 genotype was more common in cases than in controls (32.7 vs. 14.3%, p=0.041). In a model adjusted for age, BMI, duration of T2DM and renal function, and POR*1/*1 entered as a selection variable, CYP2C9*2 allele increased the hypoglycemia risk in response to sulfonylurea (odds ratio: 3.218, p=0.031). In conclusion, our results suggest that POR*28 allele is masking the association of CYP2C9*2 allele with sulfonylurea-induced hypoglycemia. Therefore, POR*28 allele is an important source of CYP2C9 activity variability and combined with CYP2C9 gene polymorphisms may explain individual variability in the effect of sulfonylureas.

[1]  M. Relling,et al.  Clinical Implementation of Pharmacogenetics: More than One Gene at a Time , 2013, Clinical pharmacology and therapeutics.

[2]  V. Manolopoulos,et al.  Association of KCNJ11 E23K gene polymorphism with hypoglycemia in sulfonylurea-treated type 2 diabetic patients. , 2012, Diabetes research and clinical practice.

[3]  T. Tracy,et al.  Effect of P450 oxidoreductase variants on the metabolism of model substrates mediated by CYP2C9.1, CYP2C9.2, and CYP2C9.3 , 2012, Pharmacogenetics and genomics.

[4]  R. Finn,et al.  NADPH – Cytochrome P 450 Oxidoreductase : Roles in Physiology , Pharmacology , and Toxicology , 2012 .

[5]  Honghao Zhou,et al.  Effects of the CYP oxidoreductase Ala503Val polymorphism on CYP3A activity in vivo: a randomized, open-label, crossover study in healthy Chinese men. , 2011, Clinical therapeutics.

[6]  V. Manolopoulos,et al.  Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective. , 2011, Pharmacogenomics.

[7]  Erkan Cüre,et al.  Mild hypoglycaemic attacks induced by sulphonylureas related to CYP2C9, CYP2C19 and CYP2C8 polymorphisms in routine clinical setting , 2011, European Journal of Clinical Pharmacology.

[8]  V. Manolopoulos,et al.  Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas. , 2009, Pharmacogenomics.

[9]  M. Bochud,et al.  The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test , 2009, Pharmacogenetics and genomics.

[10]  M. Schwab,et al.  Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation. , 2009, Pharmacogenomics.

[11]  Kathleen M. Giacomini,et al.  Genetics of P450 oxidoreductase: Sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations , 2008, Proceedings of the National Academy of Sciences.

[12]  C. Flück,et al.  Clinical, structural and functional implications of mutations and polymorphisms in human NADPH P450 oxidoreductase , 2007, Fundamental & clinical pharmacology.

[13]  V. Manolopoulos Pharmacogenomics and adverse drug reactions in diagnostic and clinical practice , 2007, Clinical chemistry and laboratory medicine.

[14]  J. Aikens,et al.  Patient-reported perceptions of side effects of antihyperglycemic medication and adherence to medication regimens in persons with diabetes mellitus. , 2007, Clinical therapeutics.

[15]  J. Brockmöller,et al.  Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. , 2005, British journal of clinical pharmacology.

[16]  L. Wienkers,et al.  Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. , 1994, Pharmacogenetics.